key: cord-0754230-nnvi3cx9
authors: Chaudhury, S.; Hutter, J. N.; Bolton, J. S.; Hakre, S.; Mose, E.; Wooten, A. I.; O'Connell, W. D.; Hudak, J.; Krebs, S. J.; Darden, J.; Regules, J. A.; Murray, C. K.; Mojarrad, K.; Peel, S. A.; Bergmann-Leitner, E. S.
title: Serological profiles of pan-coronavirus-specific responses in COVID-19 patients using a multiplexed electro-chemiluminescence-based testing platform
date: 2021-03-26
journal: nan
DOI: 10.1101/2021.03.23.21253460
sha: 64c4314b6c3b43f8632cde083410f920cd12e9b5
doc_id: 754230
cord_uid: nnvi3cx9

Serological assessment of SARS-CoV-2 specific responses are an essential tool for determining the prevalence of past SARS-CoV-2 infections in the population especially when testing occurs after symptoms have developed and limited contact tracing is in place. The goal of our study was to test a new 10-plex electro-chemiluminescence-based assay to measure IgM and IgG responses to the spike proteins from multiple human coronaviruses including SARS-CoV-2, assess the epitope specificity of the SARS-CoV-2 antibody response against full-length spike protein, receptor-binding domain and N-terminal domain of the spike protein, and the nucleocapsid protein. We carried out the assay on samples collected from three sample groups: subjects diagnosed with COVID-19 from the U.S. Army hospital at Camp Humphreys in Pyeongtaek, South Korea; healthcare administrators from the same hospital but with no reported diagnosis of COVID-19; and pre-pandemic samples. We found that the new CoV-specific multiplex assay was highly sensitive allowing plasma samples to be diluted 1:30,000 with a robust signal. The reactivity of IgG responses to SARS-CoV-2 nucleocapsid protein and IgM responses to SARS-CoV-2 spike protein could distinguish COVID-19 samples from non-COVID-19 and pre-pandemic samples. The data from the three sample groups also revealed a unique pattern of cross-reactivity between SARS-CoV-2 and SARS-CoV-1, MERS-CoV, and seasonal coronaviruses HKU1 and OC43. Our findings show that the CoV-2 IgM response is highly specific while the CoV-2 IgG response is more cross-reactive across a range of human CoVs and also showed that IgM and IgG responses show distinct patterns of epitope specificity. In summary, this multiplex assay was able to distinguish samples by COVID-19 status and characterize distinct trends in terms of cross-reactivity and fine-specificity in antibody responses, underscoring its potential value in diagnostic or serosurveillance efforts.

The current SARS-CoV-2 pandemic is unparalleled in recent history, and countries have 53 developed diverse approaches to combat and manage transmission. Most countries are attempting 54 to curtail the infection rates through strict social distancing rules, rigorous testing, and contact 55 tracing of individuals potentially exposed to infectious individuals. A population-wide serological CoV-2-specific antibody responses are reliably measurable by 2-3 weeks after onset of symptoms 67 [2] [3] [4] [5] . The presence of antibodies was detected in a minority of COVID-19 patients within one 68 week of onset and seroconversion ranges from 90 to 100% by 15 days after onset. [6, 7] . IgM 69 seroconversion is seen around 12 days from onset, and IgG seroconversion around 13 days from 70 onset [8] , with the caveat that studies on antibody response dynamics have so far largely focused 71 on convenience samples that may fail to capture the earliest emergence of these responses. 72 However, recent findings suggest the possibility of a lack of durable antibody responses, whereby 73 some percentage of individuals previously infected with SARS-CoV-2 that were seropositive 74 for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 following infection and later became seronegative during early convalescence, especially in cases 75 where the SARS-CoV-2 infection resulted in asymptomatic infection or low disease severity [9, 76 10]. This finding agrees with previous studies in humans with other coronaviruses in that antibody-77 responses to CoV infections can be short-lived [11] [12] [13] . However, the durability of SARS-CoV-2 78 responses remains poorly characterized, and it is unclear how durability varies with respect to 79 antibody fine-specificity, isotype profile, cross-reactivity to other coronaviruses, and how these 80 aspects of the humoral immunity contribute to durable protection from reinfection. 81 Although numerous SARS-CoV-2-specific serological assays have been developed [14, 82 15], additional challenges remain in using these assays for surveillance or clinical management 83 [16] including: 1) assay throughput, 2) the specificity of assay readouts to SARS-CoV-2 as 84 compared to other related coronaviruses 3) and the need to perform sample testing at multiple 85 dilutions due to the narrow linear range of the respective assay platform. Recently, we compared 86 a newly developed multiplexed serological assay based on electro-chemiluminescence (ECLIA) 87 customized for malaria serosurveillance with a qualified standard ELISA [17] . The results 88 demonstrated superiority of the ECLIA-based assay in several aspects including a wide linear 89 range eliminating the need for serial dilutions of test samples, low variability, robust 90 reproducibility of the assay, and no signal reduction due to antigenic competition when testing 91 closely related antigens. Given that only 0.1 µL of sample is needed for the assay, and with the use 92 of the pre-manufactured CoV antigen plates described here, five antigen plates (450 samples)

The objective of the current study was to test the performance of a multiplexed pan-CoV 97 ECLIA-based assay regarding its ability to establish a serological profile of responses to common 98 beta CoVs (HKU-1, OC43), MERS-CoV, SARS-CoV-1 and SARS-CoV-2. For this study, three 99 sample groups were compiled subjects diagnosed with COVID-19 from the Brian D. Allgood will enable us to compare antibody responses from COVID-19 diagnosed individuals from other 105 individuals the same location and pandemic time period, who may have been exposed, but were 106 not symptomatic or diagnosed with COVID-19. Comparison with pre-pandemic samples will 107 determine whether there are differences in CoV exposure between pre-pandemic samples and 108 pandemic samples, even in cases where there was no COVID-19 diagnosis. Our findings 109 demonstrate the utility of this assay for SARS-CoV-2-serosurveillance based on its high sensitivity 110 and specificity as well as its ability to discern between pre-existing immunity to common human to the same hospital during the same time period whose duties did not include regular interaction 120 with patients and who did not have a diagnosis of COVID-19 (these individuals were assumed to 121 be unexposed or minimally exposed from living and working in an outbreak setting with a very 122 low prevalence of COVID-19 at the time of collection); and pre-pandemic samples from several those in the same location and pandemic time period, who may have been exposed, but were not 128 symptomatic or diagnosed with COVID-19. Samples from ten COVID-19 subjects and eight 129 control subjects, matched by study location and population, were obtained and compared to a 130 similar number of pre-pandemic samples (ten) using the multiplex ECLIA assay. As this was a 131 retrospective analysis of COVID-19 samples collected during a public health investigation of a 132 local outbreak, no a priori power calculation was carried out.

All COVID-19 patients were diagnosed using a nasopharyngeal swab and RT-PCR-based 134 diagnostic assay. All Control subjects were also tested via nasopharyngeal swab and RT-PCR and 135 for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 confirmed to be negative for COVID-19 at the time of sample collection. COVID-19 disease 136 severity was assessed as asymptomatic, mild (symptomatic but not interfering with daily activity), 137 moderate (interfering with daily activity but not requiring hospitalization), and severe (preventing 138 daily activity and requiring hospitalization). All samples collected at BDAACH were sent to The MSD V-PLEX platform was used as 10-plex assays utilizing the pre-printed antigens The MSD assay provides a readout in units of mean luminescence intensity and all readouts 179 were directly log-transformed prior to analysis without any normalization or subtraction of 180 for use under a CC0 license.

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. values. Data points were colored by group, and ellipses were generated corresponding to 50% 186 confidence intervals for each group, to identify general trends in the data set. Seropositivity for 187 each CoV spike antigen for a given subject was assessed based on whether the readout for that Table 1 provides a summary of the COVID-19 subjects, date of the first positive 19 test, date of sample collection, disease severity and clinical indications as well as demographic 197 information (age range and sex). All samples were collected within three weeks of the first positive 198 COVID-19 test. One subject had severe COVID-19, six subjects had mild symptoms, and three 199 subjects were asymptomatic. Demographic information on Control subjects is shown in S 1 Table. 200 201 202 for use under a CC0 license.

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. Samples for all three groups were assayed on the MSD platform to determine IgM and IgG 206 -specific responses to influenza H3, spike proteins for SARS-CoV-2, SARS-CoV-1, MERS-CoV, 207 beta-coronaviruses OC43 and HKU1 relative to BSA (negative control) (summarized in Fig 1) . In 208 for use under a CC0 license.

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101/2021.03.23.21253460 doi: medRxiv preprint terms of assay sensitivity, we found that COVID-19 samples had a roughly 300-fold higher IgM 209 signal to SARS-CoV-2 spike protein and a 1000-fold higher IgG antibodies binding to SARS-210 CoV-2 spike antigen compared to BSA. In Control and pre-pandemic samples, there was no 211 significant difference in IgM responses to SARS-CoV-2 spike protein and BSA, but the IgG 212 response to the SARS-CoV-2 spike was approximately 10-fold higher (p < 10 -4 ) than to BSA, 213 suggesting either some degree of cross-reactivity of pre-existing IgG antibodies to SARS-CoV-2 214 spike antigen in these samples or higher non-specific IgG binding to this antigen. We carried out 215 serial dilutions to further assess assay sensitivity (S1 Fig). We found that COVID-19 samples showed significant higher IgM responses to the SARS-222 COV-2 spike protein (p<10 -7 ) than the control sample group and pre-pandemic group, while no 223 differences between the three groups were noted for BSA or influenza. On average, COVID-19 224 samples showed 100-to 200-fold higher IgM responses to SARS-CoV-2 spike antigen than the 225 control or pre-pandemic samples. For IgG responses, the COVID-19 samples also showed 226 significantly higher responses than either the control or pre-pandemic samples (p < 0.001), while 227 no differences were seen between the sample groups in terms of their reactivity to BSA or H3.

Like the IgM responses, the IgG responses in the COVID-19 samples to SARS-CoV-2 spike 229 protein were approximately 100-to 200-fold higher than in the control and pre-pandemic samples.

In both IgM and IgG responses to CoV-2 spike protein, there was a single subject in the COVID-231 for use under a CC0 license.

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Cross-reactivity of SARS-CoV-2 antibody responses 236 Next, we analyzed differences in antibody binding response to the other CoV antigens 237 between the three groups. COVID-19 subjects, in addition to showing significantly higher IgM 238 binding antibodies to SARS-CoV-2 spike compared to the Control and pre-COVID subjects, also 239 showed significantly higher IgM binding antibodies to SARS-CoV-1 (p < 0.001), HKU1 (p < 240 0.05), and OC43 (p < 0.01) spike proteins (Fig 1A) . This data suggests significant IgM cross-241 reactivity between SARS-CoV-2 and SARS CoV-1, HKU-1, and OC43. Likewise, we found that 242 COVID-19 subjects, in addition to showing significantly higher IgG binding antibodies to SARS-

CoV-2, also show significantly higher IgG binding antibodies to SARS-CoV-1 (p < 0.001) and 244 MERS-CoV (p < 0.01) spike proteins, compared with Control and pre-COVID-19 subjects, 245 suggesting that SARS-CoV-2 IgG antibodies may be cross-reactive with SARS-CoV-1 and 246 MERS-CoV (Fig 1B) .

To determine the distinguishing features between COVID-19 and non-COVID-19 samples, 248 we generated a principal component analysis (PCA) plot of the IgM and IgG responses to these 249 five CoV spike antigens (Fig 2) . The PCA using IgM data demonstrates that samples display This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. shown. Ellipses denote the 50% confidence interval for each group. 263

Seropositivity across CoV antigens 264 We next sought to determine the seropositivity of these samples across the five CoV spike 265 antigens in the panel. We defined a cutoff above which a sample would be considered seropositive 266 based on the IgG and IgM signal to BSA (noise). We set the cutoff at the upper limit of the 99.9% This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Overall, we found that 90% of the COVID-19 samples were seropositive for IgM binding 277 antibodies to SARS-CoV-2, suggesting most COVID-19 patients tested here had seroconverted by 278 the time the sample was taken (Fig 3, top) . Additionally, 33% of CoV-2-seropositive COVID-19 279 samples were also seropositive for MERS-CoV, 33% were seropositive for both SARS-CoV-1, 280 and 22% to both. By contrast, none of the Control and pre-pandemic subjects were seropositive 281 for SARS-CoV-2, and 50% of the Control and 90% of the pre-pandemic samples were seropositive 282 to none of the CoV antigens, including OC43 and HKU1, again reflecting the lack of IgM response 283 detected against these seasonal CoVs. Interestingly, 50% of Control samples were seropositive for 284 MERS-CoV, compared to none of the pre-pandemic U.S. samples.

For the IgG responses, 90% of COVID-19 samples were seropositive for SARS-CoV-2, 286 suggesting that one (of the 10) COVID-19 patients did not seroconvert at the time the sample was 287 taken (Fig 3, bottom) . Almost 60% of COVID-19 subjects that had seroconverted by IgG to 288 SARS-CoV-2 were seropositive for all four other CoVs, suggesting substantial cross-reactivity in 289 IgG SARS-CoV-2 binding antibodies. Interestingly, 25% of the subjects in the Control group 290 showed seropositivity to not only SARS-CoV-2 but also to all five of the human CoVs tested, 291 similar to what was observed in the COVID-19 group. A single subject in the COVID-19 group, 292 aforementioned Subject i-0003, was seronegative to SARS-CoV-2 in both IgM and IgG responses.

No clear association between seropositivity and symptom severity was observed in this data set.

None of the subjects in the pre-COVID-19 group showed seropositivity to SARS-CoV-2, 295 but all showed seropositivity to the seasonal betacoronaviruses HKU1 and OC43. Overall two 296 broad observations can be made from this seropositivity data: 1) IgM CoV binding antibodies This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CoVs) and 2) the IgG SARS-CoV-2 binding antibodies appear to be more cross-reactive than the 300 IgM SARS-CoV-2 binding antibodies.

Fine specificity of SARS-CoV-2 antibody responses 302

The multiplex assay contains additional antigenic targets of SARS-CoV-2, i.e., RBD, 303 NTD, and N (Fig 4) . COVID-19 patients had significantly higher IgM levels directed at these CoV-2-specific IgG responses to NTD were not significantly different between the three sample 312 groups. As before, one subject in the COVID-19 group, aforementioned Subject i-0003, was a low 313 outlier in responses to SARS-CoV-2 spike and RBD for both IgG and IgM responses.

To identify the relationship between the different antibody specificities, correlation 315 matrices were generated for IgM and IgG responses (Fig 4) demonstrating that the magnitude of 316 IgM SARS-CoV-2 spike binding antibodies correlated strongly with RBD responses. To a lesser 317 extent, there was also a positive correlation between the nucleocapsid and RBD specific antibodies.

The antibody profile of SARS-CoV-2-specific IgG was distinct from the IgM profiles as there was 319 a weak correlation between nucleocapid and spike-specific responses and NTD with RBD specific 320 antibodies, suggesting that the fine specificity between the IgM and IgG SARS-CoV-2 spike 321 responses may differ, specifically that the IgM spike binding antibodies target epitopes largely to 322 for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 the RBD, while the IgG spike binding antibodies may be more focused on epitopes that include 323 regions outside of the RBD itself, or target RBD epitopes unique to the whole-spike structure that 324 are not recapitulated in the recombinant protein. Combining IgM and IgG CoV-2 responses to identify COVID-19 samples 331 We combined all the SARS-CoV-2 specific antigen readouts (full-length spike, RBD, 332 NTD, and N) for IgM and IgG to determine if they could clearly distinguish COVID-19 samples 333 from Control or Pre-COVID-19 samples. Using an unsupervised PCA approach, we show that 334 these groups can be readily distinguished (Fig 5A) , and that even a reduction from these 12 335 parameters to two, IgG response to N and IgM response to the spike protein (Fig 5B) , was 336 sufficient to identify COVID-19 samples, for all subjects except the aforementioned Subject i- This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 by IgG, as measured by response to the SARS-CoV-2 spike protein. This apparent simultaneous 346 seroconversion was seen as early as two and three days after onset of symptoms (i-0009 and i-347 0005, respectively). This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Discussion 357

In the current study, we evaluated a new multiplex coronavirus antigen panel using an 358 electro-chemiluminescence assay platform to conduct serological high-throughput testing of 359 sera/plasma. The study had two objectives: (a) determine whether the methodology is useful for demonstrating the value of this multiplex approach for SARS-CoV-2 serology studies.

The ECLIA-based MSD platform was chosen based on its superiority in previous studies 366 using malarial antigens [17, 18] . In the present study, we evaluated a pan-CoV panel of 367 recombinant proteins generated in a mammalian expression system to ensure proper glycosylation. 368 We found that the linear range of the MSD ranged from 1:1,000 to 1:30,000, which eliminates the 369 need to test serial dilutions for individual samples. An assay with such high sensitivity and 370 specificity requires only very small sample volume (facilitating longitudinal studies), and is also 371 more likely to detect SARS-CoV-2-specific antibodies for longer periods of time after recovery.

This is critical for serosurveillance approaches, particularly in light of recent studies which report 373 sero-reversion within weeks to months of infection [19, 20] . Multiplexing the various antigens and 374 testing only at one dilution provides significant sample sparing and increases the throughput of the 375 assay. Another advantage of the MSD platform is the lack of apparent competition for antibody 376 binding between related test antigens [17] due to their physical separation within the assay wells.

Such competition has the potential to introduce significant artifacts when antigen-antibody binding 378 occurs in a liquid phase as is the case in fluorescent bead-based flow cytometry (e.g. Luminex) 379 for use under a CC0 license.

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 . This aspect is critical to the current study where the spike proteins of five CoVs are 380 simultaneously being tested.

While the ECLIA assay tests reactivity to multiple antigens simultaneously, the assay must 382 ultimately be validated against samples from individuals with known exposure to each antigen in 383 the panel to determine thresholds for seropositivity and assess the specificity. Here we provide this 384 validation for SARS-CoV-2 antigens using samples known to be exposed to SARS-CoV-2 and likely explanation is that this reflects a cross-reactivity from immunity to a related beta 391 coronavirus. On a similar note, we were surprised to find 25% IgG seropositivity for SARS-CoV-392 2 in the Control group. Given that they were all seronegative to SARS-CoV-2 by IgM, this suggests 393 the possibility of either a prior asymptomatic SARS-CoV-2 infection or cross-reactivity from 394 immunity to another coronavirus.

Assessing the serological landscape of CoV-specific IgM and IgG responses resulted in 396 several key observations: 1) IgG seropositivity to seasonal OC43 and HKU1 as well as influenza 397 H3 was high, while IgM seropositivity to these antigens was low; 2) IgM seropositivity to SARS-398 CoV-2 was highly specific, with 90% seropositivity in COVID-19 samples and 0% seropositivity This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 specificities, with IgM spike responses being largely recapitulated by the SARS-CoV-2 RBD 403 antigen, while IgG spike responses were not. Taken together these observations suggest a few 404 explanations. First, that the IgM response measured here largely reflect short-term antibody 405 responses to acute or recent infections, while the IgG response here reflects long-term memory 406 responses (in the case of the seasonal influenza H3, OC43, and HKU1) and/or later-stage, possibly 407 affinity-matured, responses (in the case of COVID-19 samples). Accordingly, the early IgM 408 response is highly specific to SARS-CoV-2 and focused on the RBD, while the late IgG response 409 is broadly cross-reactive to many CoVs and includes non-RBD or RBD-adjacent epitopes. One 410 immunological explanation for this pattern of responses is that the SARS-CoV-2 IgM response is 411 naïve-derived and thus highly specific to SARS-CoV-2, while the IgG response is largely memory-412 derived, from cross-reactive B cells from prior CoV infections, and thus biased towards conserved 413 or broadly cross-reactive SARS-CoV-2 epitopes. responses, very similar to our findings. They found that these cross-reactive CoV-2-reactive IgG 424 antibodies largely target the more highly conserved spike S2 domain, not the S1 domain that 425 for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 contains the RBD, while CoV-2 infection induced IgG and IgM antibodies target both S1 and S2 426 domains, supporting the theory that pre-existing CoV immunity is largely biased towards 427 conserved S2 epitopes. Finally, our findings suggest that for antibody-based diagnostics and 428 serosurveillance, IgM and CoV-2-N-specific responses may have higher specificity than IgG and 429 CoV-2-spike-responses, and that RBD-specific IgG responses in particular might have poor 430 sensitivity in individuals with COVID-19 whose IgG response is largely derived from pre-existing 431 CoV immunity focused on conserved S2 epitopes.

In this study, we demonstrate that by combining IgM and IgG responses to spike and N 433 proteins, the ECLIA assay platform is able to reliably distinguish COVID-19 samples from Control 434 or Pre-COVID-19 samples. IgM responses alone were found to be highly specific, but may have 435 limited durability, while IgG responses were less specific, but potentially more long-lived - 

The fact that our unsupervised approach to combining IgM and IgG responses was able to 442 distinguish COVID-19 subjects suggests that a machine-learning approach using a larger data set There were several limitations to the present study. First, the sample size is relatively small 446 and as such the study is intended primarily to demonstrate feasibility of the multiplex ECLIA 447 assay. Second, the samples were obtained through a public health investigation of a local outbreak 448 for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 in Camp Humphreys, and thus largely consists of 'convenience' samples. While we matched 449 Control subjects to the same location and study population, a rigorous case-control study was 450 infeasible in the midst of an emergency outbreak response. Still, the samples reflect diversity in 451 disease onset and severity that parallels samples collected in real-world serosurveillance efforts.

Third, with some exceptions, the study did not include longitudinal sample collection which limits 453 its findings with respect to disease progression. Fourth, while COVID-19 and Control groups were This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 26, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 

Temporal profiles of viral load in posterior oropharyngeal saliva samples and 500 serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Antibody Detection and Dynamic Characteristics in Patients with COVID-19

Antibody responses to SARS-CoV-2 in patients with COVID-19

Humoral immune response and prolonged PCR positivity in a cohort of 1343 511 SARS-CoV 2 patients in the New York City region. medRxiv, 2020: p. 2020.04.30

Understanding Antibody Testing for COVID-19

Clinical and immunological assessment of asymptomatic SARS-CoV-2 515 infections

Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 517 infection. medRxiv, 2020: p. 2020.07.09

Longitudinal profile of antibodies against SARS-coronavirus in SARS patients and 523 their clinical significance

A serological assay to detect SARS-CoV-2 seroconversion in humans

A High-Throughput Assay for Circulating Antibodies Directed Against the S 527 Protein of Severe Acute Respiratory Syndrome Coronavirus 2

Serology assays to manage COVID-19

Comparison of ELISA with electro-chemiluminescence technology for the 532 qualitative and quantitative assessment of serological responses to vaccination

Breadth of humoral immune responses to the C-terminus of the 535 circumsporozoite protein is associated with protective efficacy induced by the RTS,S malaria 536 vaccine. Vaccine

Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19

Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19

Middle East respiratory syndrome: what we learned from the 2015 outbreak in 542 the Republic of Korea

Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after 546 infection with SARS-associated coronavirus

Preexisting and de novo humoral immunity to SARS-CoV-2 in humans

It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted

The authors would like to thank Ms. Elizabeth Duncan for technical assistance at various levels of 489 the project. This study could not have been completed without the help of an excellent team of

ESB-L is a government employee. Title 17 U.S.C. § 105 provides that "Copyright protection under 467 this title is not available for any work of the United States Government, but the United States 468 Government". Title 17 U.S.C. § 101 defines US Government work as "work prepared by a military 469 service member or employee of the US Government as part of that person's official duties". The serological data expressed as Luminescence signal) are provided in S2 Table. These data are 479 raw data and were log-transformed for the downstream analysis described in the manuscript.

The authors declare that they have no competing interests.